Alprostadil (Caverject/MUSE) Regulatory Status: US, EU, Canada, UK

How Alprostadil Works: Mechanism of Action

Alprostadil is synthetic prostaglandin E1 (PGE1), a naturally occurring vasodilator that acts on smooth muscle cells in the corpus cavernosum. It binds to EP2 and EP4 prostanoid receptors, activating adenylate cyclase and raising intracellular cyclic AMP (cAMP) concentrations. The resulting smooth muscle relaxation increases arterial inflow while compressing subtunical venules, producing a rigid erection within 5 to 20 minutes of administration 1.

This mechanism bypasses the nitric oxide/cGMP pathway that PDE5 inhibitors depend on. That distinction matters clinically. Patients who fail sildenafil, tadalafil, or vardenafil because of diabetic neuropathy, radical prostatectomy, or severe vascular disease can still respond to direct intracavernosal prostaglandin delivery. In the Linet et al. trial published in the New England Journal of Medicine (N=296), 70% of men with refractory erectile dysfunction achieved erections sufficient for intercourse with alprostadil injection, compared to 7% with placebo 1.

The urethral suppository formulation (MUSE) uses a different absorption route. Alprostadil is deposited into the urethra via a single-use applicator, absorbed through urethral mucosa into the corpus spongiosum, and then transfers to the corpora cavernosa via venous communications. Efficacy is lower than injection: response rates in registration trials ranged from 43% to 65% depending on dose and etiology 2.

United States: FDA Approval and Current Status

The FDA approved Caverject (alprostadil for intracavernosal injection) on July 6, 1995, under NDA 020180, making it the first pharmacologic agent approved specifically for erectile dysfunction by injection 3. Caverject Impulse, a redesigned dual-chamber delivery system that simplified reconstitution, received approval in 2001.

MUSE (Medicated Urethral System for Erection) followed in November 1997 under NDA 020488. Vivus Inc. developed this formulation as a needle-free alternative 4. Both products carry an indication for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

Scheduling and prescribing framework. Alprostadil is not a controlled substance under the DEA Controlled Substances Act. It requires a prescription but carries no schedule classification. The first dose must be administered in a physician's office under medical supervision to calibrate the correct dose and monitor for priapism or hypotension. Patients then self-administer at home 3.

Generic availability. Generic alprostadil for injection became available in the US after patent expiry. Multiple manufacturers now supply 10 mcg, 20 mcg, and 40 mcg vials. MUSE remains branded, with no FDA-approved generic urethral suppository as of May 2026.

Insurance coverage. Coverage varies widely. Medicare Part D plans typically exclude erectile dysfunction drugs under the Social Security Act exclusion (Section 1862). Commercial insurers may cover alprostadil with prior authorization documenting PDE5 inhibitor failure, though many classify it as a lifestyle medication 5.

European Union: National Authorizations Across Member States

Alprostadil was never approved through the European Medicines Agency (EMA) centralized procedure. Instead, it holds national marketing authorizations in individual EU member states through mutual recognition and decentralized procedures. This creates meaningful variation in brand names, available strengths, and reimbursement across the EU.

Key brand names in the EU:

• Caverject and Caverject Dual Chamber (Pfizer) in most Western European markets
• Viridal Duo (UCB/Schwarz Pharma) in Germany, Austria, and several Central European states
• Edex (Schwarz Pharma) in France and Belgium
• MUSE (Meda/Mylan) available in select EU markets

In Germany, alprostadil injection is available by prescription and partially reimbursed through statutory health insurance (GKV) when prescribed for organic erectile dysfunction with documented PDE5 inhibitor failure. A 2017 German Federal Social Court ruling expanded reimbursement criteria for men with severe organic ED 6.

France lists alprostadil injection under the Autorisation de mise sur le marché system. Edex 10 mcg and 20 mcg are available by prescription with partial Sécurité sociale reimbursement (15% rate as of 2024) when prescribed for documented organic erectile dysfunction 7.

EU prescribing pattern differences. European urologists prescribe alprostadil injection as second-line therapy following the European Association of Urology (EAU) Guidelines on Sexual and Reproductive Health, which recommend intracavernosal injection after PDE5 inhibitor failure. The EAU guidelines assign a Grade A recommendation for alprostadil monotherapy or as part of trimix (alprostadil + papaverine + phentolamine) 8.

Canada: Health Canada Approvals

Health Canada approved Caverject (alprostadil sterile powder for intracavernosal injection) under Drug Identification Number (DIN) 02141329. MUSE is also authorized, distributed by Paladin Labs (now Endo International's Canadian subsidiary).

Alprostadil is classified as a Schedule I drug under the National Association of Pharmacy Regulatory Authorities (NAPRA) scheduling framework, meaning it requires a prescription and must be dispensed by a pharmacist 9. The first injection must be performed in a clinical setting for dose titration.

Provincial formulary status. Most provincial drug benefit programs do not list alprostadil on their formularies. Ontario's Ontario Drug Benefit (ODB) program excludes it. British Columbia's PharmaCare program similarly does not cover it. Patients typically pay out-of-pocket or through private insurance, with Caverject costing approximately CAD $30 to $50 per injection and MUSE ranging from CAD $20 to $35 per suppository.

Canadian clinical practice. The Canadian Urological Association (CUA) guidelines on erectile dysfunction management position alprostadil injection as second-line therapy after oral agents, consistent with the American Urological Association (AUA) framework. The CUA notes that intracavernosal injection remains the most effective non-surgical treatment, with response rates exceeding 70% across etiologies 10.

United Kingdom: Post-Brexit MHRA Framework

Before Brexit, alprostadil was authorized in the UK through the EU mutual recognition procedure. Since January 1, 2021, existing marketing authorizations were automatically converted to UK marketing authorizations regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).

Caverject 10 mcg and 20 mcg powder and solvent for solution for injection hold active UK marketing authorizations. MUSE 250 mcg, 500 mcg, and 1000 mcg urethral sticks are also authorized. All are classified as Prescription Only Medicines (POM) under the Human Medicines Regulations 2012 11.

NHS prescribing. The NHS can prescribe alprostadil for erectile dysfunction, but coverage falls under Selected List Scheme (SLS) restrictions. The Drug Tariff specifies that NHS prescriptions for erectile dysfunction treatments are limited to men who meet one of several qualifying criteria:

• Treatment for prostate cancer, prostatectomy, radical pelvic surgery, or renal failure
• Spinal cord injury or spina bifida
• Diabetes mellitus
• Multiple sclerosis or Parkinson's disease
• Poliomyelitis or single-gene neurological disease
• Severe distress documented by a specialist

Men who do not meet SLS criteria can obtain a private prescription. The approximate UK cost for Caverject 20 mcg is £12 to £18 per injection on private prescription 11.

NICE guidance. The National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summary on erectile dysfunction recommends alprostadil intracavernosal injection or urethral application as second-line treatment when PDE5 inhibitors are contraindicated, ineffective, or not tolerated. NICE recommends starting with the lowest effective dose and titrating under medical supervision 12.

Comparative Regulatory Summary Across Jurisdictions

Regulatory differences between the four jurisdictions affect clinical access in concrete ways. The prescription-only classification is universal, as is the requirement for initial in-office dose titration. Divergence appears in reimbursement, generic availability, and which formulations are marketed.

The US offers the broadest range of generic options for injection but provides the least public insurance coverage. Germany reimburses the most generously among EU states for organic ED. The UK's SLS system creates a two-tier access model, splitting patients into NHS-eligible and private-pay categories based on underlying diagnosis rather than clinical need. Canada's provincial exclusions push most patients to out-of-pocket payment.

Dose form availability by jurisdiction:

• Intracavernosal injection. Available in all four jurisdictions. Branded (Caverject, Edex/Viridal) and generic options exist in the US and EU. Canada and UK primarily stock branded Caverject.
• Urethral suppository (MUSE). Available in the US, UK, and Canada. EU availability is limited to select member states.
• Topical cream (Vitaros). Approved in some EU member states (notably the UK pre-Brexit, and currently in several EU countries) but not FDA-approved in the US or authorized in Canada. Contains 300 mcg alprostadil in a topical cream formulation applied to the urethral meatus 13.

Safety Monitoring Requirements Across Regulatory Frameworks

All four regulatory agencies mandate similar safety monitoring protocols, though enforcement mechanisms differ. The most consistent requirement across jurisdictions is the in-office first-dose protocol. This exists because alprostadil carries a 1% to 3% risk of prolonged erection (defined as lasting 4 to 6 hours) and a 0.4% risk of priapism (erection exceeding 6 hours requiring intervention) based on post-marketing surveillance data 1.

The FDA requires a boxed warning about priapism risk on Caverject labeling. The EU Summary of Product Characteristics (SmPC) for Caverject and Viridal includes priapism in the "Special warnings and precautions for use" section. Health Canada's Product Monograph mirrors the FDA language closely.

Penile fibrosis monitoring. Long-term alprostadil injection use carries a 3% to 8% risk of penile fibrosis or Peyronie's-like plaques, depending on injection frequency and technique 14. The FDA label recommends periodic penile examination. EAU guidelines suggest clinical assessment every 3 to 6 months for patients using regular intracavernosal therapy. The MHRA's patient information leaflet instructs patients to report any penile curvature or lumps immediately.

"Patients who self-inject more than three times per week or who use alprostadil at doses above 60 mcg face a significantly elevated risk of corporal fibrosis," noted the AUA Second-Line Therapies Panel in their 2018 guideline update 15.

Cardiovascular screening. Although alprostadil itself does not carry the same cardiovascular contraindication profile as PDE5 inhibitors (it does not interact with nitrates), all four regulatory bodies recommend cardiovascular fitness assessment before initiating any erectile dysfunction treatment. The Princeton III Consensus Guidelines recommend that men be stratified into low, intermediate, or high cardiovascular risk before starting ED therapy, regardless of drug class 16.

Off-Label and Compounded Use: Regulatory Gray Areas

While alprostadil is approved as monotherapy, it is frequently used as a component of bi-mix (alprostadil + papaverine) or tri-mix (alprostadil + papaverine + phentolamine) compounded formulations. These combinations are not FDA-approved, EMA-authorized, or approved by Health Canada or the MHRA. They exist in a regulatory gray zone governed by pharmacy compounding regulations rather than drug approval frameworks.

In the US, Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound patient-specific prescriptions. Section 503B governs outsourcing facilities that compound without individual prescriptions. The FDA has issued warning letters to compounding pharmacies for quality violations in tri-mix production, citing potency and sterility failures 3.

The UK permits compounding under Section 10 of the Medicines Act 1968 (now superseded by the Human Medicines Regulations 2012), allowing registered pharmacies to prepare unlicensed medicines against a valid prescription. EU regulations vary by member state. Canada permits compounding under provincial pharmacy regulations.

"Tri-mix compounding fills a genuine unmet need for patients who require lower alprostadil doses combined with synergistic agents, but the lack of standardized formulations raises quality control concerns," stated the 2023 International Society for Sexual Medicine (ISSM) position statement on intracavernosal therapy 17.

Pipeline and Regulatory Outlook

No new alprostadil formulations are currently under active FDA review. Vitaros (topical alprostadil cream), approved in the EU and the UK, has not been submitted for FDA approval as of May 2026. The patent and data exclusivity protections for original Caverject formulations have expired in all four jurisdictions, opening the market to generic manufacturers.

Biosimilar considerations do not apply to alprostadil because it is a small-molecule synthetic prostaglandin, not a biologic. Generic approval follows the standard abbreviated pathway (ANDA in the US, Article 10.1 in the EU, ANDS in Canada).

The regulatory trajectory for alprostadil is stable. No jurisdiction is considering reclassification to over-the-counter status. The injection route and priapism risk make OTC conversion unlikely under current regulatory frameworks. Patients in all four jurisdictions should expect continued prescription-only access with in-office titration requirements maintained for the foreseeable future.

The maximum recommended frequency across all approved labels is once daily, with a minimum 24-hour interval between doses and a ceiling of 60 mcg per injection for Caverject 3.